Details

Autor(en) / Beteiligte

• Nakazaki, Kiyoshi
• Yomo, Shoji
• Kondoh, Takeshi
• Serizawa, Toru
• Kenai, Hiroyuki
• Kawagishi, Jun
• Sato, Sonomi
• Nagano, Osamu
• Aiyama, Hitoshi
• Kawai, Hideya
• Hasegawa, Toshinori
• Iwai, Yoshiyasu
• Nagatomo, Yasushi
• Kida, Yoshihisa
• Nishigaki, Masakazu

Titel

Salvage gamma knife radiosurgery for active brain metastases from small-cell lung cancer after whole-brain radiation therapy: a retrospective multi-institutional study (JLGK1701)

Ist Teil von

• Journal of neuro-oncology, 2020-03, Vol.147 (1), p.67-76

Ort / Verlag

New York: Springer US

Erscheinungsjahr

2020

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• Purpose To evaluate the efficacy of gamma knife radiosurgery (GKS) for brain metastases (BMs) from small-cell lung cancer after whole-brain radiotherapy (WBRT). Methods We retrospectively analyzed the usefulness and safety of GKS in 163 patients from 15 institutions with 1–10 active BMs after WBRT. The usefulness and safety of GKS were evaluated using statistical methods. Results The median age was 66 years, and 79.1% of patients were men. The median number and largest diameter of BM were 2.0 and 1.4 cm, respectively. WBRT was administered prophylactically in 46.6% of patients. The median overall survival (OS) was 9.3 months, and the neurologic mortality was 20.0%. Crude incidences of local control failure and new lesion appearance were 36.6% and 64.9%, respectively. A BM diameter ≥ 1.0 cm was a significant risk factor for local progression (hazard ratio [HR] 2.556, P = 0.039) and neurologic death (HR 4.940, P = 0.031). Leukoencephalopathy at the final follow-up was more prevalent in the therapeutic WBRT group than in the prophylactic group (P = 0.019). The symptom improvement rate was 61.3%, and neurological function was preserved for a median of 7.6 months. Therapeutic WBRT was not a significant risk factor for OS, neurological death, local control, or functional deterioration (P = 0.273, 0.490, 0.779, and 0.560, respectively). Symptomatic radiation-related adverse effects occurred in 7.4% of patients. Conclusions GKS can safely preserve neurological function and prevent neurologic death in patients with 1–10 small, active BMs after prophylactic and therapeutic WBRT.